Authors: Rothenberg, ML Kuhn, JG Schaaf, LJ Rodriguez, GI Eckhardt, SG Villalona-Calero, MA Rinaldi, DA Hammond, LA Hodges, S Sharma, A Elfring, GL Petit, RG Locker, PK Miller, LL von Hoff, DD

Citation: Ml. Rothenberg et al., Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks, ANN ONCOL, 12(11), 2001, pp. 1631-1641

Authors: Socinski, MA Sandler, AB Miller, LL Locker, PK Hanover, CK Elfring, GL Israel, VK Pirotta, N Natale, RB

Citation: Ma. Socinski et al., Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 19(4), 2001, pp. 1078-1087

Authors: Saltz, LB Cox, JV Blanke, C Rosen, LS Fehrenbacher, L Moore, MJ Maroun, JA Ackland, SP Locker, PK Pirotta, N Elfring, GL Miller, LL

Citation: Lb. Saltz et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer., N ENG J MED, 343(13), 2000, pp. 905-914

Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML

Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696